A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Moein Amin
Study ID
NCT07222956
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Multiple Sclerosis (MS) Primary Progressive
  • Multiple Sclerosis (MS) Secondary Progressive

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Oct 30, 2030
Completion
Dec 30, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Remibrutinib, active administration
    100 mg remibrutinib, twice daily

Primary Outcome Measure

Quantitative MRI volumetric measurements [ Time Frame: Baseline to Month 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland ClinicClevelandOhio44195
Bryan Davies, RN
[email protected]
216-444-5253
John Mays
[email protected]
216-445-6339

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic· Cleveland, OH

Related Studies